Publications by authors named "Eric Helmer"

Claim this Profile
P
Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial.
Marta Neve, Paul M Diderichsen, Eric Helmer, Dick de Vries, Amit Taneja

ACR Open Rheumatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
Jeremy Perrier, Virginie Gualano, Eric Helmer, Florence Namour, Viera Lukacova

Clin Transl Sci· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Toby M Maher, Paul Ford, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Eric Helmer

JAMA· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.
Irina R Strambu, Christian A Seemayer, Liesbeth M-C A Fagard, Paul A Ford, Tom A K Van der Aa, Eric G Helmer

Eur Respir J· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziritaxestat Drug-Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition.
Eric Helmer, Negin Karimian, Karen Van Assche, Ineke Seghers, Sandrine Le Tallec

Clin Pharmacol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration.
Eric Helmer, Ashley Willson, Christopher Brearley, Mark Westerhof, Stephane Delage

Clin Pharmacol Drug Dev· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies.
Julie Desrivot, Tim Van Kaem, Lisa Allamassey, Eric Helmer

Clin Pharmacol Drug Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects.
Helen Timmis, Tim Van Kaem, Julie Desrivot, Sonia Dupont, Luc Meuleners, Eric Helmer

Clin Pharmacol Drug Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Maria Juarez, Nieves Diaz, Geoffrey I Johnston, Saba Nayar, Andrew Payne, Eric Helmer

Rheumatology (Oxford)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Nieves Diaz, Maria Juarez, Caterina Cancrini, Maximilian Heeg, Pere Soler-Palacín, Eric Helmer

J Immunol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.
Jean-Marie Nicolas, Hugues Chanteux, Johan Nicolaï, Frédéric Brouta, Delphine Viot, Eric Helmer

Eur J Pharm Sci· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
Ellen van der Aar, Julie Desrivot, Sonia Dupont, Bertrand Heckmann, Ann Fieuw, Eric Helmer

J Clin Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D Flynn, Anna Moltó, Eric Helmer

Ann Rheum Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [ C]Seletalisib (UCB5857) in Healthy Subjects.
Eric Helmer, Jean-Marie Nicolas, Jeff Long, Ad F Roffel, Emma Jones

J Clin Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Sophie Glatt, Eric Helmer, Birgit Haier, Foteini Strimenopoulou, Graham Price

Br J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.
Eric Helmer, Mark Watling, Emma Jones, Dominique Tytgat, Mark Jones

Eur J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis